YANG Minghui, ZHOU Xiaoping, JIANG Dongli. Progress in the Studies on AKR1B10 Inhibitors[J]. Chinese Journal of Modern Applied Pharmacy, 2017, 34(1): 135-142. DOI: 10.13748/j.cnki.issn1007-7693.2017.01.032
    Citation: YANG Minghui, ZHOU Xiaoping, JIANG Dongli. Progress in the Studies on AKR1B10 Inhibitors[J]. Chinese Journal of Modern Applied Pharmacy, 2017, 34(1): 135-142. DOI: 10.13748/j.cnki.issn1007-7693.2017.01.032

    Progress in the Studies on AKR1B10 Inhibitors

    • Aldo-keto reductase family1 member10(AKR1B10) is a member of AKR1 family, which belongs to the aldehyde ketone reductase superfamily(AKRs). Aldo-keto reductase may participate in the different biological processes in different organisms, including carbonyl detoxification, osmotic adjustment, hormone metabolism, lipid synthesis, diabetes complications and formation of tumor. Currently, AKR1B10 has proved to be specific expression in tumor cells and narrowly distributed in normal tissue. Therefore, cancer drugs which are targeted with AKR1B10 have already won widely attention. In this study, the research progress in recent years for AKR1B10 inhibitors was summarized. AKR1B10 inhibitors are classified into natural compound inhibitors and chemical synthesis inhibitors. Furthermore, the chemical structure and the related structural modifications for suppressing influenced the active and selective strength of AKR1B10 inhibitors.
    • loading

    Catalog

      Turn off MathJax
      Article Contents

      /

      DownLoad:  Full-Size Img  PowerPoint
      Return
      Return